Markets

Insider Trading

Hedge Funds

Retirement

Opinion

7 Best ASX Stocks to Buy Now

Page 1 of 7

In this article, we will discuss the 7 Best ASX Stocks to Buy Now.

While the Australian market is relatively well-positioned, it is vulnerable to broader market shocks, says SG Hiscock & Company (an Australian boutique investment manager). During the meeting on May 20, the RBA Board decided to reduce the cash rate target by 0.25% to 3.85%. For the broader market, the critical feature of this meeting, as well as the media briefing, was confirmation that the Board assessed the possibility of an even larger rate cut of 0.5%. Considering the still-elevated levels of global uncertainty, the RBA is expected to take a cautiously dovish stance toward further rate cuts, as per Grant Feng (Vanguard Senior Economist).

What Lies Ahead for the Australian Economy?

There has been some easing of the US-China trade tensions, reducing the external uncertainty and growth concerns, added Feng. Overall, Feng expects the Australian economy to grow ~2% over 2025, with the easing of policy partly mitigating the impact of uncertainty. The inflation is expected to stay in the 2%–3% band targeted by the RBA, though it is expected to be in the upper half of this range. Furthermore, the supply-side weakness, mainly the lackluster productivity growth, is expected to hold back progress on disinflation, added Feng.

Amidst these trends, let us now have a look at the 7 Best ASX Stocks to Buy Now.

An experienced fund advisor setting parameters on investments with remaining maturities of one to three years.

Our Methodology

To list the 7 Best ASX Stocks to Buy Now, we used a screener to shortlist the ASX stocks listed on the US exchanges. After getting the list, we chose the ones popular among hedge funds, as of Q1 2025. Finally, the stocks have been ranked in ascending order of their hedge fund sentiments.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

7 Best ASX Stocks to Buy Now

7. Telix Pharmaceuticals Limited (NASDAQ:TLX)

Number of Hedge Fund Holders: N/A

Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the 7 Best ASX Stocks to Buy Now. On June 23, the company announced that the US FDA approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting.

This update gets applied to Illuccix’s third indication, for selecting patients who are indicated for PSMA-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the approval by the US FDA of an expanded label for Pluvicto® (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after the treatment with androgen receptor pathway inhibitor (ARPI) therapy and before chemotherapy. Now that RLT is approved for earlier usage in the patient journey, the clinical utilization of Illuccix® is projected to increase by a minimum of 20,000 scans annually.

In Q1 2025, Telix Pharmaceuticals Limited (NASDAQ:TLX)’s unaudited revenue came in at ~$186 million, representing an increase of 62% over the prior year corresponding quarter (Q1 2024: $115 million) and a QoQ rise of 31% (Q4 2024: $142 million). This includes $151 million from global sales of Illuccix® and $33 million from RLS Radiopharmacies (RLS) since the acquisition was completed on 27 January 2025.

Telix Pharmaceuticals Limited (NASDAQ:TLX) stated that Illuccix continued to gain market share and maintain price stability amidst competition. Furthermore, Telix Pharmaceuticals Limited (NASDAQ:TLX) happens to be the only company with 2 FDA-approved PSMA-PET imaging agents – Illuccix and Gozellix. This allows it to broaden patient reach and maximize choice for the customers. Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock has a consensus one-year price target of $22.90.

Page 1 of 7

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!